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3Summary32
AIMS33
Antiplatelet drugs are often discontinued early after ischaemic stroke, either because of poor34
compliance, complications or withdrawal of care. It is unclear whether this places patients at35
increased risk of recurrence. We explored the association between cardiovascular event rate36
and persistence with prescribed antiplatelet drugs.37
METHODS38
We used a matched case-control design using the Virtual International Stroke Trials Archive39
(VISTA). Cases were patients who had an acute coronary syndrome, recurrent stroke or40
transient ischaemic attack within 90 days post-stroke and were matched for age ±10 years41
and sex with up to four controls. Antiplatelet use was categorized as persistent (used for > 342
days and continued up to day 90), early cessation (used antiplatelet < 3 days) or43
stopped/interrupted users (used for > 3 days but stopped prior to day 90). These categories44
were compared in cases and controls using a conditional logistic regression model that45
adjusted for potential confounders.46
RESULTS47
A total of 970 patients were included, of whom 194 were cases and 776 were matched48
controls. At 90 days, 10 cases (5.2%) and 58 controls (7.5%) stopped/interrupted their49
antiplatelet. The risk of cardiovascular event was not different in stopped/interrupted users50
(adjusted OR 0.70, 95% CI 0.33, 1.48; P=0.352) and early cessations (adjusted OR 1.04,51
95% CI 0.62, 1.74; P=0.876) when compared to persistent users.52
CONCLUSION53
We found no increased risk in patients who stopped and interrupted antiplatelets early after54
stroke but the study was limited by a small sample size and further research is needed.55
56
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4WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT59
Antiplatelet therapy is recommended for secondary prevention after ischaemic stroke.60
Interrupting or stopping antiplatelet therapy increases the risk of cardiovascular events.61
62
WHAT THIS STUDY ADDS63
The study did not demonstrate a significantly increased risk with stopping or interrupting64
antiplatelet use early afte stroke. This may reassure clinicians that, where interruption to65
therapy is needed for clinical reasons, there is not a significant increase in short term risk.66
67
68
69
70
Introduction71
There is a risk of recurrence following acute ischaemic stroke [1]. Antiplatelet therapy is72
given to reduce this risk and the risk of other vascular outcomes [2, 3]. National Institute for73
Health and Clinical Excellence (NICE) and Scottish Intercollegiate Guidelines Network74
(SIGN) guidelines recommend that antiplatelet therapy must be started early and continued75
indefinitely for long term secondary stroke prevention [3, 4]. In the UK guidelines favour76
aspirin therapy for 2-weeks followed by clopidogrel or the combination of low-dose aspirin77
and dipyridamole.78
79
Persistence with antiplatelet regimens is variable after stroke. Rates of aspirin80
discontinuation of less than 10% to almost 50% reported [5, 6]. At one year as many as 50%81
of patients who were prescribed aspirin or clopidogrel either discontinued, or failed to adhere82
to their regimen [7-9]. This may be for several reasons including patient non-compliance,83
bleeding complications, financial pressures, or physician directed withdrawal due to84
withdrawal of care, intercurrent illness or planned procedures [10]. Interrupting or stopping85
5antiplatelet therapy may increase the risk of cardiovascular events in patients with a history86
of cardiovascular or cerebrovascular disease [11, 12]. One study found that among the 219787
cases of ischaemic stroke, 5.2% cases occurred within 60 days after antithrombotic88
withdrawal [10]. In this study, stroke events were clustered mostly in the first 7 days after89
stopping medication. Antithrombotic medication was stopped for various reasons including90
being stopped by physicians for procedures, patient compliance, bleeding complications and91
cost. In another study by García Rodríguez et al. [11], among 673 patients who had92
diagnosed with ischaemic stroke or TIA, 71.3% patients were taking aspirin on the day of93
event and 10% discontinued aspirin within 31-180 days before the event. On the other hand,94
a recent prospective observational study found that interruption of antiplatelet therapy due to95
surgical necessity was not associated with increased risk of cardiovascular events [13].96
97
Data to demonstrate the impact of stopping antiplatelet therapy early after ischaemic stroke,98
where recurrence rate is highest are lacking. We aimed to explore the rate of antiplatelet99
cessation and interruption in a sample of patients with recent ischaemic stroke and assess100
the risk of cardiovascular events associated with cessation and interruption of antiplatelet101
drugs.102
103
Methods104
Study design105
We used a matched case-control study design to examine association between antiplatelet106
exposure and risk of a cardiovascular event. We used individual matching to identify up to107
four controls for each case, matched by age ±10 years and sex. We followed the STROBE108
guidance in reporting this case-control study [14].109
110
Data sources111
6We used data from the Virtual International Stroke Trials Archive (VISTA) [15]. VISTA is a112
collaborative registry that collates and provides access to anonymised data from completed113
clinical trials. VISTA data are stored at the Robertson Centre for Biostatistics, University of114
Glasgow, Glasgow, UK. VISTA contains patients’ demographic data such as age, sex and115
ethnicity; smoking history and co-morbid conditions as well as details on the index stroke,116
and functional outcome measures. Adverse events (AE) data, laboratory measurements and117
prescribed medications are available from certain trials. All trials lodged in VISTA already118
have local institutional review board approved procedures in accordance with the119
Declaration of Helsinki. Thus, our analysis does not require a new study approval.120
Nevertheless, access to data is subject to approval by the steering committee.121
122
Study cohort123
All acute ischaemic stroke patients in the VISTA who took antiplatelet therapy and had124
complete information on initiation day of antiplatelet therapy were identified. Patients with125
concurrent use of vitamin K antagonist such as warfarin were excluded as it may influence126
clinical [16] and safety [17] outcomes in acute ischaemic stroke patients. Patients who had a127
cardiovascular event within the first two days after ischaemic stroke were excluded as the128
event might not be associated to antiplatelet but due to the specific pattern of ischaemic129
changes after acute stroke [18].130
131
Cases were defined as patients who had at least one cardiovascular event in the first 90132
days after acute ischaemic stroke. A cardiovascular event was defined as a acute coronary133
syndrome (ACS), recurrent ischaemic stroke or TIA. The event was identified from AE and134
SAE reports datasets using these key terms: (a) for ACS - unstable angina, acute coronary135
syndrome or myocardial infarction; (b) for recurrent ischaemic stroke - stroke, cerebral136
infarction or cerebrovascular accident; and (c) TIA - transient ischaemic attack. Controls137
were identified from the same source to minimize the potential of bias [19]. Controls were138
7defined as patients who had no cardiovascular event within 90 days after acute ischaemic139
stroke. The flowchart of patient’s selection are shown in Figure 1. The sample size was140
determined by the number of cases available in the study cohort.141
142
Antiplatelet drug exposure143
The information on antiplatelet drugs was obtained from the current medication dataset in144
VISTA. Data on start and stop dates of antiplatelet drugs were available on certain trials that145
had monitored start and stop dates for all medications. Antiplatelet drugs were identified146
using the World Health Organization’s Anatomical Therapeutic Chemical (ATC)147
classifications i.e. antiplatelet with ATC code: B01AC. The antiplatelet exposure period for148
each patient began after the diagnosis of acute ischaemic stroke and ended at the index149
date. The index date was the date of the first cardiovascular event recorded after antiplatelet150
exposure in cases. In controls it was the same date as the matched case [20, 21]. Exposure151
to antiplatelet drugs prior to the index date was classified as persistent use, early cessation,152
interruption, or stopped (Figure 2). Persistent use was defined as taking antiplatelet therapy153
up to, or within 3 days of the index date. Patients who switching to another antiplatelet154
therapy were considered as continuing antiplatelet treatment. Early cessation was defined as155
patient who took antiplatelet therapy less than three days post-stroke or prior to the index156
date. Interruption was defined as taking antiplatelet therapy up to, or within 3 days of the157
index date, but with two days or more interrupted use. Stopped was defined as stopping158
antiplatelet therapy at least 5 days before the index date.159
160
Bleeding events161
Bleeding events occurring during the study period were divided into two categories162
(intracerebral haemorrhage (ICH) and extracranial haemorrhage (ECH)). Intracerebral163
haemorrhage included all types of ICH except haemorrhagic transformation 1 and 2 of164
cerebral infarction, which were not counted. ECH was defined as all other types of bleeding165
8and was split into gastrointestinal (GI) and non-GI bleeding. These information were166
extracted from AE and SAE datasets in VISTA.167
168
Statistical analysis169
Descriptive statistics were recorded for cases and controls and according to the three types170
of antiplatelet exposures. The Chi-square test was used to compare baseline characteristics171
between cases and controls. Comparison between antiplatelet exposures group were172
conducted using the Kruskal-Wallis test or the chi-square test depending on the distribution173
and nature of the data. Categorical variables were summarised using frequencies and174
proportions and continuous variables as mean [standard deviation (SD)] or median175
[interquartile range (IQR)].176
177
We used conditional logistic regression to calculate odds ratios (OR) and 95% confidence178
intervals (95% CI) for risk of cardiovascular event associated with exposures of antiplatelet179
before the index date. We first conducted univariable analyses. In multivariable analysis, we180
first included all significant variables (first model). We then consecutively dropped the least181
significant variable until all included variables were significant at P<0.05 (final model). A182
P<0.05 was considered significant. Point estimates and 95% CI are presented for all results.183
We used a complete-case approach to analysis so there was no imputation of missing data.184
All analyses were performed using IBM SPSS Statistics version 21.0 [22].185
186
A post-hoc power analysis to determine the power of the study and the sample size needed187
to detect a desired degree of statistical power was performed using PS (version 3.0 2009) to188
address the likelihood of type II error.189
190
Results191
Study population192
9Complete data were available for analysis of antiplatelet exposure in 4050 patients. Of thses,193
a total of 194 patients who had at least one cardiovascular event (126 ischaemic stroke, 45194
ACS and 23 TIA) within 90 days following acute ischaemic stroke. These cases were195
matched to 776 controls. Baseline characteristics of patients with cardiovascular event and196
their matched controls are shown in Table 1. Compared with the control group, the cases197
were more likely to have a history of diabetes, heart failure and previous TIA. Among cases,198
there were 136 (70.1%) persistent users, 48 (24.7%) with early cessation and 10 (5.2%)199
stopped/interrupted users. Among controls, there were 534 (68.8%) persistent users, 184200
(23.7%) early cessation and 58 (7.5%) stopped/interrupted users.201
202
Patients who interrupted/stopped their antiplatelet therapy had higher baseline NIHSS and203
were more likely to have previous ischaemic heart disease and stroke (Table 2) than204
persistent users. Aspirin was the most common antiplatelet prescribed followed by205
clopidogrel for both cases and controls (Table 3). More than two-third of persistent users,206
early cessation and interrupted/stopped users were exposed to aspirin and followed by207
clopidogrel (Table 4). The occurrence of bleeding events was highest in interrupted/stopped208
users (10.3%) followed by early cessation users (7.6%) (Table 5).209
210
Antiplatelet exposure and cardiovascular event211
There was no significant difference in cardiovascular event rate in early cessation and212
interrupted/stopped users compared to persistent users on univariable analysis (OR 1.07,213
95% CI 0.67, 1.71; P=0.784 and OR 0.67, 95% CI 0.34, 1.36; P=0.269 respectively) (Table214
6). Results were similar following adjustment (adjusted OR 1.04, 95% CI 0.62, 1.74; P=0.876215
and OR 0.70; 95% CI 0.33, 1.48; P=0.352 respectively) (Table 7).216
217
Discussion218
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We performed a nested case-control study to explore the relationship between stopping or219
interrupting antiplatelet drugs and cardiovascular risk in patients with recent ischaemic220
stroke. We found no evidence for an increased risk of cardiovascular among patients who221
stopped or had interrupted use of antiplatelets.222
223
We found that the rates of early cessation of antiplatelet therapy were higher in our study224
compared to others [23, 24]. We defined early cessation as taking an antiplatelet for fewer225
than 3 days post-stroke or before a cardiovascular event. We used this definition because226
most patients took aspirin and fewer than 3 days of aspirin use is unlikely to lead to full227
inhibition of platelets [25].228
229
Withdrawal of antiplatelets is associated with an increase in thromboxane A2 activity [26]230
which could increase the risk of ischaemic stroke [10, 11, 27]. These studies found that231
discontinuation of antiplatelet therapy within one to six months is associated with increased232
risk of ischaemic stroke or TIA. We did not see an increase and several factors could explain233
the difference between our findings and previous studies. First, our sample size was small234
compared to the studies by García Rodríguez, et al. [11] and Broderick, et al. [10] so there is235
a risk of type 2 error. Further, previous studies have assessed different time periods and236
clinical scenarios. The study cohort in García Rodríguez et al. was followed up for237
approximately 3.4 years. The STRATAGEM trial assessed the interruption of antiplatelets in238
patients undergoing surgery [28] and found no increased risk. This suggests the risk of239
stopping or interrupting antiplatelet drugs may be acceptable in the short term and we240
wished to assess whether this was the case after stroke.241
242
After stroke, there are several reasons why clinicians may be faced with decisions regarding243
continuing or stopping anti-platelets. These include bleeding complications and other244
adverse events such as worsening stroke symptoms or changes in haematological245
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measures. At present, little data exist to inform these decisions in terms of risk of recurrence246
following cessation. Our study should reassure that, if clinically indicated, the short term risk247
of stopping anti-platelets does not appear to be significantly increased.248
249
In the present study, comorbidity was more common in cases and stroke severity was higher250
in patients who were interrupted or stopped users. We also found stroke severity, age,251
hypertension, diabetes and quality of life were related to the pattern of anti-platelet use.252
Patients with higher stroke severity, previous stroke and lower life quality were more likely to253
stop. Although we cannot be sure, this likely reflects the underlying reasons for stopping254
treatment, such as change in clinical condition or withdrawal of care. Early cessation users255
had a higher rate of atrial fibrillation which may be explained by decisions to start256
anticoagulation therapy. On the other hand, interrupted/stopped users had a higher rate of257
bleeding suggesting this also influenced the reason to interrupt or stop antiplatelet therapy.258
259
Strengths and limitations260
Despite their known problems of bias and confounding, case-control designs are efficient in261
examining the association between outcomes and exposures. VISTA database sample262
provided data that were prospectively collected during clinical trials in patients with263
confirmed ischaemic stroke. We minimized selection bias by including all cases of264
cardiovascular event within the selected time period (day 3 up to 90 days) and matched265
controls, free of the outcome of interest and independent of the exposure of interest.266
Matching for age and sex increased the precision of our results compared with those of267
previous unmatched case-control studies. Information on exposures was recorded in the268
database, eliminating recall bias.269
270
An important limitation of this study is the lack of information on the underlying reasons for271
interruption/stopping of antiplatelets. This limits the generalizability of our findings to clinical272
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practice. Generalizability is further limited by the fact that data come from a clinical trial273
registry and because most patients took aspirin and few received the combination of aspirin-274
dipyridamole or clopidogrel as recommended in national and international guidelines. The275
main limitation is study power. Althought there is a large number of cases and controls, the276
number of patients with the different antiplatelet exposures was limited. Post hoc analysis277
revealed that this study, at alpha <0.05, with 194 cases and matched with four controls has278
insufficient power (0.239). Thus, to obtain 80% power, with the level of alpha 0.05, 801279
cases with 4 matched controls per case are needed.280
281
Conclusion282
We found no significant association between interrupted or stopped use of antiplatelets and283
risk of cardiovascular events. This might reassure clinicians who need to stop antiplatelets284
for clinical reasons. However, our study had limited power and a clinically important risk285
cannot be excluded. Further research is needed.286
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Figures425
426
Figure 1. Flowchart of patients’ selection.427
428
Figure 2. Determination of persistent user (a), early cessation user (b), interrupted user (c)429
and stopped user (d) of antiplatelet exposure. AP, antiplatelet; CV, cardiovascular event.430
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Table 1. Characteristics of patients with cardiovascular event and their matched controls431
Characteristics
No. (%)
p-valueOverall
n=970
Cases
n=194
Controls
n=776
Age, years* 70.9(10.8) 70.9(11.3) 70.9(10.7) NA‡
Male sex 510(52.6) 102(52.6) 408(52.6) NA‡
Caucasian 808/934(86.5) 161/187(86.1) 647/747(86.6) 0.905
Current Smoker 267/936(28.5) 60/187(32.1) 207/749(27.6) 0.240
Baseline NIHSS† 12(8-17) 11.5(8-17) 12(8-17) 0.886
Medical history
Hypertension 692/947(73.1) 147/194(75.8) 545/753(72.4) 0.365
Diabetes 228/970(23.5) 61/194(31.4) 167/776(21.5) 0.004
Atrial fibrillation 159/947(16.8) 37/194(19.1) 122/753(16.2) 0.389
Heart failure 65/859(7.6) 20/184(10.9) 45/675(6.7) 0.060
Ischaemic heart
disease 243/915(26.6) 57/187(30.5) 186/728(25.5) 0.194
Previous TIA 69/901(7.7) 19/176(10.8) 50/725(6.9) 0.084
Previous stroke 177/886(20.0) 40/186(21.5) 137/700(19.6) 0.606
rt-PA 318(32.8) 70(36.1) 248(32.0) 0.305
Antiplatelet exposures
Early cessation 232(23.9) 48(24.7) 184(23.7) 0.520
Stopped/Interrupted 68(7.0) 10(5.2) 58(7.5)
Persistent 670(69.1) 136(70.1) 534(68.8)
*Values are reported as mean (SD); †median (IQR); ‡Variables that were matched and432
hence not applicable. CI, confidence interval; IQR, interquartile range; NIHSS, National433
Institute Health Stroke Scale; TIA, transient ischaemic attack; rt-PA, recombinant tissue434
plasminogen activator; SD, standard deviation.435
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Table 2. Distribution of risk factors for cardiovascular event by antiplatelet exposure436
Characteristics
No. (%)
p-valuePersistent
user
n=670
Early
cessation user
n=232
Interrupted/
Stopped user
n=68
Age, years* 70.2(10.9) 73.6(10.0) 69.1(11.3)
Male sex 351(52.4) 122(52.6) 37(54.4) 0.951
Ethnicity,
Caucasian
556/646 197/222 55/66 0.444
(86.1) (88.7) (83.3)
Current Smoker
185/643 57/226 25/67 0.152
(28.8) (25.2) (37.3)
Baseline NIHSS† 11(8-16) 13(9-17) 17(12-20) <0.001
Medical history
Hypertension
473/654 169/225 50/68 0.716
(72.3) (75.1) (73.5)
Diabetes
164/670 51/232 13/68 0.502
(24.5) (22.0) (19.1)
Atrial fibrillation
91/654 56/225 12/68 0.001
(13.9) (24.9) (17.6)
Heart failure
38/601 21/196 6/62 0.105
(6.3) (10.7) (9.7)
Ischaemic heart
disease
146/628 74/220 23/67 0.004
(23.2) (33.6) (34.3)
Previous TIA
48/623 16/212 5/66 0.997
(7.7) (7.5) (7.6)
Previous stroke
111/617 48/207 18/62 0.049
(18.0) (23.2) (29.0)
rt-PA 224(33.4) 74(31.9) 20(29.4) 0.755
*Values are reported as mean (SD); †median (IQR). CI, confidence interval; IQR,437
interquartile range; NIHSS, National Institute Health Stroke Scale; TIA, transient ischaemic438
attack; rt-PA, recombinant tissue plasminogen activator; SD, standard deviation.439
440
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Table 3. Characteristics of antiplatelet regimen prescribed441
Antiplatelet regimen
No. (%)
Unadjusted
OR (95% CI) p-valueCases
n=194
Controls
n=776
Aspirin 139(71.6) 566(72.9) 1.00 -
Clopidogrel 28(14.4) 105(13.5) 1.10 (0.69-1.74) 0.674
Aspirin+Clopidogrel 10(5.2) 25(3.2) 1.63 (0.75-3.52) 0.215
Aspirin+Dipyridamole 10(5.2) 50(6.4) 0.82 (0.40-1.68) 0.585
Ticlopidine 4(2.1) 16(2.1) 1.01 (0.34-3.05) 0.980
Aspirin+Ticlopidine 1(0.5) 1(0.1) 4.44 (0.28-71.29) 0.293
Carbasalate 1(0.5) 5(0.6) 0.76 (0.09-6.73) 0.825
Dipyridamole 1(0.5) 5(0.6) 0.79 (0.09-6.73) 0.825
Ozagrel 0(0.0) 1(0.1) - -
Triflusal 0(0.0) 2(0.3) - -
CI, confidence interval; OR, odds ratio.442
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Table 4. Frequency of antiplatelet regimen according to types of antiplatelet exposure444
Antiplatelet regimen
No. (%)
p-value*Persistent
user
n=670
Early
cessation user
n=232
Interrupted/
Stopped user
n=68
Aspirin 492(73.4) 160(69.0) 53(77.9) -
Clopidogrel 88(13.1) 38(16.4) 7(10.3) 0.267
Aspirin+Clopidogrel 20(3.0) 12(5.2) 3(4.4) 0.238
Aspirin+Dipyridamole 43(6.4) 13(5.6) 4(5.9) 0.948
Ticlopidine 13(1.9) 7(3.0) 0(0.0) 0.291
Aspirin+Ticlopidine 2(0.3) 0(0.0) 0(0.0) 1.000
Carbasalate 6(0.9) 0(0.0) 0(0.0) 0.467
Dipyridamole 4(0.6) 2(0.9) 0(0.0) 0.774
Ozagrel 0(0.0) 0(0.0) 1(1.5) 0.076
Triflusal 2(0.3) 0(0.0) 0(0.0) 1.000
*Compared with aspirin.445
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Table 5. Frequency of bleeding events following antiplatelet exposure446
Bleeding
No. (%)
Persistent
user
n=670
Early
cessation user
n=232
Interrupted/
Stopped user
n=68
Overall
n=970
ICH 7(1.1) 6(2.7) 5(7.5) 18(1.9)
ECH 21(3.2) 12(5.4) 2(2.9) 35(3.7)
Total bleeding 28(4.2) 18(7.6) 7(10.3) 53(5.5)
ICH, intracranial haemorrhage; ECH, extracranial haemorrhage.447
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Table 6. Univariate analyses (conditional logistic regression) of selected variables against448
outcome of being “case”449
Characteristics
No. (%)
Unadjusted
OR (95% CI) p-valueCases
n=194
Controls
n=776
Ethnicity
Caucasian 161/187 (86.1) 647/747 (86.6) 0.94 (0.58-1.51) 0.782
Others 26/187 (13.9) 100/747 (13.4) 1.00
Smoking history
Current Smoker 60/187 (32.1) 207/749 (27.6) 1.25 (0.87-1.79) 0.219
Non/Former Smoker 127/187 (67.9) 542/749 (72.4) 1.00
Baseline NIHSS* 11.5 (8-17) 12 (8-17) 0.99 (0.97-1.02) 0.886
Medical history
Hypertension
Yes 147/194 (75.8) 545/753 (72.4) 1.19 (0.82-1.72) 0.356
No 47/194 (24.2) 208/753 (27.6) 1.00
Diabetes
Yes 61/194 (31.4) 167/776 (21.5) 1.71 (1.20-2.46) 0.003
No 133/194 (68.6) 609/776 (78.5) 1.00
Atrial fibrillation
Yes 37/194 (19.1) 122/753 (16.2) 1.27 (0.82-1.95) 0.285
No 157/194 (80.9) 631/753 (83.8) 1.00
Heart failure
Yes 20/184 (10.9) 45/675 (6.7) 1.80 (1.01-3.20) 0.046
No 164/184 (89.1) 630 (93.3) 1.00
IHD
Yes 57/187 (30.5) 186/728 (25.5) 1.26 (0.89-1.80) 0.208
No 130/187 (69.5) 542/728 (74.5) 1.00
Previous TIA
Yes 19/176 (10.8) 50/725 (6.9) 1.78 (1.01-3.15) 0.049
No 157/176 (89.2) 675/725 (93.1) 1.00
Previous stroke
Yes 40/186 (21.5) 137/700 (19.6) 1.08 (0.72-1.62) 0.700
No 146/186 (78.5) 563/700 (80.4) 1.00
rt-PA
Yes 70 (36.1) 248 (32.0) 1.20 (0.87-1.66) 0.267
No 124 (63.9) 528 (68.0) 1.00
Antiplatelet exposures
Early cessation 48 (24.7) 184 (23.7) 1.07 (0.67-1.71) 0.784
Stopped/Interrupted 10 (5.2) 58 (7.5) 0.67 (0.34-1.36) 0.269
Persistent 136 (70.1) 534 (68.8) 1.00
All values are reported as no. (%) unless otherwise noted. †Values are reported as median450
(IQR). CI, confidence interval; IHD, ischaemic heart disease; IQR, interquartile range;451
NIHSS, National Institute Health Stroke Scale; OR, odds ratio; TIA, transient ischaemic452
attack; rt-PA, recombinant tissue plasminogen activator.453
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Table 7. Multivariable conditional logistic regression of explanatory variables against454
outcome of being “case”455
Characteristics Adjusted OR (95% CI) p-value*
First model, all variables
Caucasian 0.89 (0.52-1.54) 0.684
Current Smoker 1.18 (0.77-1.81) 0.442
Baseline NIHSS 0.98 (0.95-1.02) 0.331
Hypertension 1.04 (0.65-1.67) 0.862
Diabetes 1.60 (1.03-2.49) 0.036
Atrial fibrillation 1.32 (0.76-2.29) 0.318
Heart failure 1.33 (0.69-2.55) 0.398
Ischemic heart disease 0.99 (0.65-1.50) 0.964
Previous TIA 2.15 (1.15-4.01) 0.016
Previous stroke 0.97 (0.59-1.59) 0.896
rt-PA 1.05 (0.72-1.54) 0.787
Early cessation† 1.09 (0.60-1.96) 0.779
Stopped/Interrupted† 0.72 (0.32-1.65) 0.441
Final model
Diabetes 1.72 (1.170-2.52) 0.006
Previous TIA 1.90 (1.06-3.40) 0.031
Early cessation AP† 1.04 (0.62-1.74) 0.876
Stopped/Interrupted AP† 0.70 (0.33-1.480) 0.352
*Adjusted for other variables in model. †Compared to Persistent users. AP, antiplatelet; CI,456
confidence interval; NIHSS, National Institutes of Health Stroke Scale; OR, odds ratio; rt-PA,457
recombinant tissue plasminogen activator; TIA, transient ischaemic attack.458
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Tables of Links459
460
461
462
463
464
465
466
467
468
469
These Tables of Links list key protein targets and ligands in this article that are hyperlinked*470
to corresponding entries in http://www.guidetopharmacology.org, the common portal for data471
from the IUPHAR/BPS Guide to PHARMACOLOGY [29], and are permanently archived in472
the Concise Guide to PHARMACOLOGY 2015/16 [30-34].473
LIGANDS
aspirin dipyridamole
clopidogrel ticlopidine
TARGETS
G protein-coupled
receptors [30]
P2Y1 receptor P2Y12 receptor
Enzymes [31]
COX-2 CYP2B6
Phosphodiesterases, 3',5'-
cyclic nucleotide
Ion channels [32]
ASICs
Transporter [33]
SLC29 family
Other Protein Targets [34]
regulator of G-protein
signaling 18
